pMAGE-A1278-286 specific CD8+ cytotoxic T lymphocytes

pMAGE-A1278-286 specific CD8+ cytotoxic T lymphocytes (CTLs) are a type of cell therapy product engineered to express T cell receptors (TCRs) that specifically recognize the MAGEA1(278-286) peptide presented by MHC class I molecules on cancer cells[4]. These CTLs are designed to selectively target and kill cancer cells expressing the MAGEA1 tumor antigen, leveraging the natural cytotoxic function of CD8+ T cells. The approach belongs to the category of T cell receptor engineered T cell (TCR-T) therapy, a personalized immunotherapy strategy. The mechanism involves isolating or engineering CD8+ T cells to express a TCR that recognizes MAGEA1(278-286), then expanding these cells ex vivo before adoptive transfer to the patient. The response is evaluated based on T cell expansion, cytokine release, and cytotoxic activity against MAGEA1-expressing tumor cells[4]. No specific clinical trial or commercial product for this exact TCR specificity was identified in the provided search results.

Other names

MAGEA1(278-286) epitope-specific cytotoxic T lymphocytes